Aziz Burgy is a savvy and seasoned Hatch-Waxman practitioner. Aziz has litigated over seventy such cases in the last ten years. He has served as lead counsel to clients in a multitude of venues including the Patent Trial and Appeal Board (PTAB), U.S. district courts, U.S. Court of Appeals for the Federal Circuit (CAFC), U.S. Court of Federal Claims, and the U.S. International Trade Commission. Aziz has represented clients in various post-grant proceedings before the U.S. Patent Trial and Appeal Board. Most recently, Aziz was instrumental in getting seven patents held unpatentable via inter partes review. Aziz also has experience representing clients in FDA regulatory matters, including recently defeating AstraZeneca’s temporary restraining order, thereby enabling immediate launch of generic versions of Crestor®. Aziz also has experience representing clients from a wide range of technologies, including medical devices, pharmaceuticals, internet security systems, industrial robotics, computer software and GPS technology in a variety of forums, including U.S. District Courts, U.S. Court of Appeals for the Federal Circuit and the U.S. International Trade Commission. Aziz has established himself as a distinguished force in IP litigation.
Aziz is a frequent lecturer on U.S. intellectual property rights, with an emphasis on Hatch-Waxman issues. He has also taught classes on intellectual property at George Mason University. Not only is Aziz at the forefront of patent jurisprudence, he has also helped shape legislation related to patent laws. Specifically, Aziz has advised clients and Congress on various patent legislation matters dealing with the America Invents Act (AIA).
Last updated October 2019